-transparent.png){kind=logo}
The distribution of FK506 in the blood was estimated in-vitro. At a drug level of 5 ng mL-1, FK506 mainly distributed in erythrocytes (95-98%) in dog, monkey and human blood, and its distribution was affected by drug concentration, temperature, and haematocrit values. In erythrocytes most of FK506 was distributed in cytoplasmic components and was bound strongly to a protein having a molecular weight of 10-11 kDa. The molecular weight of this protein agrees with FK506-binding protein found in various cells. Greater than 98.8% of FK506 was bound to the plasma proteins in all species studied. FK506 bound to various plasma proteins such as lipoproteins, globulins, alpha 1-acid glycoprotein and albumin.
K Nagase, and
K Iwasaki, and
K Nozaki, and
K Noda
September 1988,
Transplantation,
K Nagase, and
K Iwasaki, and
K Nozaki, and
K Noda
February 2001,
The Journal of allergy and clinical immunology,
K Nagase, and
K Iwasaki, and
K Nozaki, and
K Noda
July 2020,
Pharmaceutical research,
K Nagase, and
K Iwasaki, and
K Nozaki, and
K Noda
July 1993,
Biological & pharmaceutical bulletin,
K Nagase, and
K Iwasaki, and
K Nozaki, and
K Noda
February 1994,
The Journal of investigative dermatology,
K Nagase, and
K Iwasaki, and
K Nozaki, and
K Noda
January 1993,
Carcinogenesis,
K Nagase, and
K Iwasaki, and
K Nozaki, and
K Noda
March 1992,
Pharmaceutical research,
K Nagase, and
K Iwasaki, and
K Nozaki, and
K Noda
January 1976,
Canadian journal of biochemistry,
K Nagase, and
K Iwasaki, and
K Nozaki, and
K Noda
February 2016,
Biochemical and biophysical research communications,
K Nagase, and
K Iwasaki, and
K Nozaki, and
K Noda
January 1990,
Therapeutic drug monitoring,
